The clinical efficacy of cGMP-specific sildenafil on mitochondrial biogenesis induction and renal damage in cats with acute on chronic kidney disease.
Azotemia
Cat
Mitochondrial biogenesis
Sildenafil citrate
Urinary biomarker
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
24
07
2024
accepted:
22
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Mitochondrial biogenesis (MB) induction has recently emerged as potential therapeutic approaches in kidney pathology and the mitochondria-targeted therapies should be investigated to improve treatment of animals with kidney diseases. This study aimed to investigate the effects of MB induction with sildenafil citrate on the cGMP/NO pathway, glomerular filtration, and reduction of kidney damage and fibrosis (TGF-β/SMAD pathway) in cats with acute on chronic kidney disease (ACKD). Thirty-three cats were divided into the non-azotemic (healthy) group (n:8) and the ACKD group (n:25), comprising different breeds, sexes, and ages. Sildenafil citrate was administered to the non-azotemic and ACKD groups (2.5 mg/kg, PO, q12 hours) for 30 days. Serum and urine NO, MDA, NGAL, KIM-1, TGF-β1, IL-18, FGF 23, PGC-1α and cGMP concentrations were measured. Serum cGMP concentrations increased (P < 0.05) in the non-azotemic group during the 2 While sildenafil citrate has been determined to induce a low level of MB and to have a beneficial effect on glomerular filtration, it is observed to be ineffective in mitigating renal damage and fibrosis via the TGF-β/SMAD pathway in cats with ACKD.
Sections du résumé
BACKGROUND
BACKGROUND
Mitochondrial biogenesis (MB) induction has recently emerged as potential therapeutic approaches in kidney pathology and the mitochondria-targeted therapies should be investigated to improve treatment of animals with kidney diseases. This study aimed to investigate the effects of MB induction with sildenafil citrate on the cGMP/NO pathway, glomerular filtration, and reduction of kidney damage and fibrosis (TGF-β/SMAD pathway) in cats with acute on chronic kidney disease (ACKD). Thirty-three cats were divided into the non-azotemic (healthy) group (n:8) and the ACKD group (n:25), comprising different breeds, sexes, and ages. Sildenafil citrate was administered to the non-azotemic and ACKD groups (2.5 mg/kg, PO, q12 hours) for 30 days. Serum and urine NO, MDA, NGAL, KIM-1, TGF-β1, IL-18, FGF 23, PGC-1α and cGMP concentrations were measured.
RESULTS
RESULTS
Serum cGMP concentrations increased (P < 0.05) in the non-azotemic group during the 2
CONCLUSIONS
CONCLUSIONS
While sildenafil citrate has been determined to induce a low level of MB and to have a beneficial effect on glomerular filtration, it is observed to be ineffective in mitigating renal damage and fibrosis via the TGF-β/SMAD pathway in cats with ACKD.
Identifiants
pubmed: 39478527
doi: 10.1186/s12917-024-04345-9
pii: 10.1186/s12917-024-04345-9
doi:
Substances chimiques
Sildenafil Citrate
BW9B0ZE037
Cyclic GMP
H2D2X058MU
Nitric Oxide
31C4KY9ESH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
499Subventions
Organisme : The Scientific and Technological Research Council of Türkiye (TUBİTAK)
ID : 120O988
Organisme : The Scientific Research Projects Coordinatorship of Selcuk University (SUBAP)
ID : 22401056
Informations de copyright
© 2024. The Author(s).
Références
Stallons LJ, Whitaker RM, Schnellmann RG. Suppressed mitochondrial biogenesis in folic acid-induced acute kidney injury and early fibrosis. Toxicol Lett. 2014;224(3):326–32. https://doi.org/10.1016/j.toxlet.2013.11.014 .
doi: 10.1016/j.toxlet.2013.11.014
pubmed: 24275386
Rasbach KA, Schnellmann RG. Signaling of mitochondrial biogenesis following oxidant injury. J Biol Chem. 2007;282(4):2355–62. https://doi.org/10.1074/jbc.M608009200 .
doi: 10.1074/jbc.M608009200
pubmed: 17116659
Funk JA, Schnellmann RG. Accelerated recovery of renal mitochondrial and tubule homeostasis with SIRT1/PGC-1α activation following ischemia-reperfusion injury. Toxicol Appl Pharm. 2013;273(2):345–54. https://doi.org/10.1016/j.taap.2013.09.026 .
doi: 10.1016/j.taap.2013.09.026
Whitaker RM, Wills LP, Stallons LJ, Schnellmann RG. cGMP-Selective phosphodiesterase inhibitors stimulate mitochondrial Biogenesis and promote recovery from Acute kidney Injury. J Pharmacol Exp Ther. 2013;347(3):626–34. https://doi.org/10.1124/jpet.113.208017 .
doi: 10.1124/jpet.113.208017
pubmed: 24042162
Zhang XQ, Agborbesong E, Li XG. The role of Mitochondria in Acute kidney Injury and chronic kidney Disease and its therapeutic potential. Int J Mol Sci. 2021;22(20). https://doi.org/10.3390/ijms222011253 .
Cowgill LD, Polzin DJ, Elliott J, Nabity MB, Segev G, Grauer GF et al. Is Progressive chronic kidney disease a slow acute kidney Injury? Vet Clin N Am-Small. 2016;46(6):995–; https://doi.org/10.1016/j.cvsm.2016.06.001
Chen H, Dunaevich A, Apfelbaum N, Kuzi S, Mazaki-Tovi M, Aroch I, et al. Acute on chronic kidney disease in cats: etiology, clinical and clinicopathologic findings, prognostic markers, and outcome. J Vet Intern Med. 2020;34(4):1496–506. https://doi.org/10.1111/jvim.15808 .
doi: 10.1111/jvim.15808
pubmed: 32445217
Bagshaw SM, Gibney RT. Conventional markers of kidney function. Crit Care Med. 2008;36(4 Suppl):S152–8. https://doi.org/10.1097/CCM.0b013e318168c613 .
doi: 10.1097/CCM.0b013e318168c613
pubmed: 18382187
Devarajan P. Proteomics for biomarker discovery in acute kidney injury. Semin Nephrol. 2007;27(6):637–51. https://doi.org/10.1016/j.semnephrol.2007.09.005 .
doi: 10.1016/j.semnephrol.2007.09.005
pubmed: 18061846
Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol. 2008;23(12):2151–7. https://doi.org/10.1007/s00467-007-0470-x .
doi: 10.1007/s00467-007-0470-x
pubmed: 17394022
IRIS. IRIS staging of CKD (modified 2019). http://www.iris-kidney.com/pdf/IRIS_Staging_of_CKD_modified_2019.pdf (2019). Accessed 5.02.2024.
Christov M, Neyra JA, Gupta S, Leaf DE. Fibroblast growth factor 23 and Klotho in AKI. Semin Nephrol. 2019;39(1):57–75. https://doi.org/10.1016/j.semnephrol.2018.10.005 .
doi: 10.1016/j.semnephrol.2018.10.005
pubmed: 30606408
Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Bba-Mol Cell Res. 2011;1813(7):1269–78. https://doi.org/10.1016/j.bbamcr.2010.09.019 .
doi: 10.1016/j.bbamcr.2010.09.019
Aparicio-Trejo OE, Tapia E, Sánchez-Lozada LG, Pedraza-Chaverri J. Mitochondrial bioenergetics, redox state, dynamics and turnover alterations in renal mass reduction models of chronic kidney diseases and their possible implications in the progression of this illness. Pharmacol Res. 2018;135:1–11. https://doi.org/10.1016/j.phrs.2018.07.015 .
doi: 10.1016/j.phrs.2018.07.015
pubmed: 30030169
Tang CY, Cai J, Yin XM, Weinberg JM, Venkatachalam MA, Dong Z. Mitochondrial quality control in kidney injury and repair. Nat Rev Nephrol. 2021;17(5):299–318. https://doi.org/10.1038/s41581-020-00369-0 .
doi: 10.1038/s41581-020-00369-0
pubmed: 33235391
Cowgill L. Grading of acute kidney injury (2016). http://www.iris-kidney.com/pdf/4_ldc-revised-grading-of-acute-kidney-injury.pdf (2016). Accessed 5.02.2024.
Hall JA, Fritsch DA, Jewell DE, Burris PA, Gross KL. Cats with IRIS stage 1 and 2 chronic kidney disease maintain body weight and lean muscle mass when fed food having increased caloric density, and enhanced concentrations of carnitine and essential amino acids. Vet Rec. 2019;184(6). https://doi.org/10.1136/vr.104865 .
Grauer GF. Utility of Creatinine, UPC, and SDMA in the early diagnosis of CKD in dogs and cats (updated 2019). http://www.iris-kidney.com/education/utility_creatine_early_diagnosis_ckd.html (2019). Accessed 5.02.2024.
Bragato N, Borges NC, Fioravanti MCS. B-mode and doppler ultrasound of chronic kidney disease in dogs and cats. Vet Res Commun. 2017;41(4):307–15. https://doi.org/10.1007/s11259-017-9694-9 .
doi: 10.1007/s11259-017-9694-9
pubmed: 28634673
Dunaevich A, Chen H, Musseri D, Kuzi S, Mazaki-Tovi M, Aroch I, et al. Acute on chronic kidney disease in dogs: etiology, clinical and clinicopathologic findings, prognostic markers, and survival. J Vet Intern Med. 2020;34(6):2507–15. https://doi.org/10.1111/jvim.15931 .
doi: 10.1111/jvim.15931
pubmed: 33044036
Debruyn K, Haers H, Combes A, Paepe D, Peremans K, Vanderperren K, et al. Ultrasonography of the feline kidney: technique, anatomy and changes associated with disease. J Feline Med Surg. 2012;14(11):794–803. https://doi.org/10.1177/1098612X12464461 .
doi: 10.1177/1098612X12464461
pubmed: 23087005
Yan GY, Chen KY, Wang HC, Ma TY, Chen KS. Relationship between ultrasonographically determined renal dimensions and International Renal Interest Society stages in cats with chronic kidney disease. J Vet Intern Med. 2020;34(4):1464–75. https://doi.org/10.1111/jvim.15814 .
doi: 10.1111/jvim.15814
pubmed: 32585054
Brown SA, Finco DR, Brown CA, Crowell WA, Alva R, Ericsson GE, et al. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. Am J Vet Res. 2003;64(3):321–7. https://doi.org/10.2460/ajvr.2003.64.321 .
doi: 10.2460/ajvr.2003.64.321
pubmed: 12661873
Duffy ME, Specht A, Hill RC. Comparison between urine protein: Creatinine ratios of samples obtained from dogs in Home and Hospital settings. J Vet Intern Med. 2015;29(4):1029–35. https://doi.org/10.1111/jvim.12836 .
doi: 10.1111/jvim.12836
pubmed: 26059431
Allerton F. BSAVA small animal formulary. Part A: Canine and feline. 2020.
Polzin DJ, Churchill JA. Controversies in Veterinary Nephrology: renal diets are indicated for cats with International Renal Interest Society Chronic Kidney Disease Stages 2 to 4: the Pro View. Vet Clin North Am Small Anim Pract. 2016;46(6):1049–65. https://doi.org/10.1016/j.cvsm.2016.06.005 .
doi: 10.1016/j.cvsm.2016.06.005
pubmed: 27485277
Quimby JM, Update on Medical Management of Clinical Manifestations of Chronic Kidney Disease. Vet Clin North Am Small Anim Pract. 2016;46(6):1163–81. https://doi.org/10.1016/j.cvsm.2016.06.004 .
doi: 10.1016/j.cvsm.2016.06.004
pubmed: 27593576
Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression, 3rd Edition. Wiley Ser Probab St. 2013:1-500; https://doi.org/10.1002/9781118548387
Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest. 2004;125(2):580–6. https://doi.org/10.1378/chest.125.2.580 .
doi: 10.1378/chest.125.2.580
pubmed: 14769741
Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, et al. Cardioprotection with phosphodiesterase-5 inhibition–a novel preconditioning strategy. J Mol Cell Cardiol. 2004;36(2):165–73. https://doi.org/10.1016/j.yjmcc.2003.11.001 .
doi: 10.1016/j.yjmcc.2003.11.001
pubmed: 14871543
Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, et al. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol. 2005;42(5–6):219–32. https://doi.org/10.1016/j.vph.2005.02.010 .
doi: 10.1016/j.vph.2005.02.010
pubmed: 15922255
Gasanov F, Aytac B, Vuruskan H. The effects of tadalafil on renal ischemia reperfusion injury: an experimental study. Bosnian J Basic Med. 2011;11(3):158–62.
doi: 10.17305/bjbms.2011.2567
Sohotnik R, Nativ O, Abbasi A, Awad H, Frajewicki V, Armaly Z, et al. Phosphodiesterase-5 inhibition attenuates early renal Ischemia-Reperfusion-Induced Acute kidney Injury: Assessment by quantitative measurement of urinary ngal and Kim-1. Nephrol Dial Transpl. 2013;28:98.
Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY, Lim SJ. Effects of Sildenafil on oxidative and inflammatory injuries of the kidney in Streptozotocin-Induced Diabetic rats. Am J Nephrol. 2009;29(3):274–82. https://doi.org/10.1159/000158635 .
doi: 10.1159/000158635
pubmed: 18812693
Akgul T, Huri E, Yagmurdur H, Ayyildiz A, Ustun H, Germiyanoglu C. Phosphodiesterase 5 inhibitors attenuate renal tubular apoptosis after partial unilateral ureteral obstruction: an experimental study. Kaohsiung J Med Sci. 2011;27(1):15–9. https://doi.org/10.1016/j.kjms.2010.03.001 .
doi: 10.1016/j.kjms.2010.03.001
pubmed: 21329887
Ebrahimi F, Shafaroodi H, Asadi S, Nezami BG, Ghasemi M, Rahimpour S, et al. Sildenafil decreased cardiac cell apoptosis in diabetic mice: reduction of oxidative stress as a possible mechanism. Can J Physiol Pharm. 2009;87(7):556–64. https://doi.org/10.1139/Y09-036 .
doi: 10.1139/Y09-036
Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol. 2000;190(3):255–66. doi: Doi 10.1002/(Sici)1096–9896(200002)190:3 < 255::Aid-Path526 > 3.0.Co;2–6.
doi: 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6
pubmed: 10685060
Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol. 2003;14(8):2199–210. https://doi.org/10.1097/01.Asn.0000079785.13922.F6 .
doi: 10.1097/01.Asn.0000079785.13922.F6
pubmed: 12874476
Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012;298:229–317. https://doi.org/10.1016/B978-0-12-394309-5.00006-7 .
doi: 10.1016/B978-0-12-394309-5.00006-7
pubmed: 22878108
Abdel-latif RG, Morsy MA, El-Moselhy MA, Khalifa MA. Sildenafil protects against nitric oxide deficiency-related nephrotoxicity in cyclosporine A treated rats. Eur J Pharmacol. 2013;705(1–3):126–34. https://doi.org/10.1016/j.ejphar.2013.02.039 .
doi: 10.1016/j.ejphar.2013.02.039
pubmed: 23499693
Halling JF, Pilegaard H. PGC-1alpha-mediated regulation of mitochondrial function and physiological implications. Appl Physiol Nutr Metab. 2020;45(9):927–36. https://doi.org/10.1139/apnm-2020-0005 .
doi: 10.1139/apnm-2020-0005
pubmed: 32516539
Chambers JM, Wingert RA. PGC-1α in disease: recent renal insights into a versatile metabolic regulator. Cells. 2020;9(10):2234.
doi: 10.3390/cells9102234
pubmed: 33022986
Casemayou A, Fournel A, Bagattin A, Schanstra J, Belliere J, Decramer S, et al. Hepatocyte nuclear Factor-1beta controls mitochondrial respiration in renal tubular cells. J Am Soc Nephrol. 2017;28(11):3205–17. https://doi.org/10.1681/ASN.2016050508 .
doi: 10.1681/ASN.2016050508
pubmed: 28739648
Rasbach KA, Schnellmann RG. PGC-1alpha over-expression promotes recovery from mitochondrial dysfunction and cell injury. Biochem Biophys Res Commun. 2007;355(3):734–9. https://doi.org/10.1016/j.bbrc.2007.02.023 .
doi: 10.1016/j.bbrc.2007.02.023
pubmed: 17307137
Huang S, Jin Y, Zhang L, Zhou Y, Chen N, Wang W. PPAR gamma and PGC-1alpha activators protect against diabetic nephropathy by suppressing the inflammation and NF-kappaB activation. Nephrol (Carlton). 2024. https://doi.org/10.1111/nep.14381 .
doi: 10.1111/nep.14381
Kang HM, Ahn SH, Choi P, Ko Y-A, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21(1):37–46.
doi: 10.1038/nm.3762
pubmed: 25419705
Peng H, Wang Q, Lou T, Qin J, Jung S, Shetty V, et al. Myokine mediated muscle-kidney crosstalk suppresses metabolic reprogramming and fibrosis in damaged kidneys. Nat Commun. 2017;8(1):1493. https://doi.org/10.1038/s41467-017-01646-6 .
doi: 10.1038/s41467-017-01646-6
pubmed: 29138395
Andersson KE. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Brit J Pharmacol. 2018;175(13):2554–65. https://doi.org/10.1111/bph.14205 .
doi: 10.1111/bph.14205
Shah SV. The role of reactive oxygen metabolites in Glomerular-Disease. Annu Rev Physiol. 1995;57:245–62.
doi: 10.1146/annurev.ph.57.030195.001333
pubmed: 7778867
Schopfer FJ, Baker PR, Freeman BA. NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? Trends Biochem Sci. 2003;28(12):646–54. https://doi.org/10.1016/j.tibs.2003.10.006 .
doi: 10.1016/j.tibs.2003.10.006
pubmed: 14659696
Araujo M, Welch WJ. Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hy. 2006;15(1):72–7. https://doi.org/10.1097/01.mnh.0000191912.65281.e9 .
doi: 10.1097/01.mnh.0000191912.65281.e9
Sharma M, Zhou ZM, Miura H, Papapetropoulos A, McCarthy ET, Sharma R, et al. ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide. Am J Physiol-Renal. 2009;296(6):F1386–95. https://doi.org/10.1152/ajprenal.90369.2008 .
doi: 10.1152/ajprenal.90369.2008
Mack RM, Hegarty E, McCrann DJ, Michael HT, Grauer GF. Longitudinal evaluation of symmetric dimethylarginine and concordance of kidney biomarkers in cats and dogs. Vet J. 2021;276:105732. https://doi.org/10.1016/j.tvjl.2021.105732 .
doi: 10.1016/j.tvjl.2021.105732
pubmed: 34391920
Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534–43. https://doi.org/10.1097/01.Asn.0000088027.54400.C6 .
doi: 10.1097/01.Asn.0000088027.54400.C6
pubmed: 14514731
Wang IC, Hsu WL, Wu PH, Yin HY, Tsai HJ, Lee YJ. Neutrophil Gelatinase-Associated Lipocalin in cats with naturally occurring chronic kidney disease. J Vet Intern Med. 2017;31(1):102–8. https://doi.org/10.1111/jvim.14628 .
doi: 10.1111/jvim.14628
pubmed: 28019047
Wu PH, Hsu WL, Tsai PSJ, Wu VC, Tsai HJ, Lee YJ. Identification of urine neutrophil gelatinase-associated lipocalin molecular forms and their association with different urinary diseases in cats. Bmc Vet Res. 2019;15(1). https://doi.org/10.1186/s12917-019-2048-9 .
Bland SK, Cote O, Clark ME, DeLay J, Bienzle D. Characterization of kidney injury molecule-1 in cats. J Vet Intern Med. 2014;28(5):1454–64. https://doi.org/10.1111/jvim.12428 .
doi: 10.1111/jvim.12428
pubmed: 25274439
Bland SK, Schmiedt CW, Clark ME, DeLay J, Bienzle D. Expression of kidney Injury Molecule-1 in healthy and diseased feline kidney tissue. Vet Pathol. 2017;54(3):490–510. https://doi.org/10.1177/0300985817690213 .
doi: 10.1177/0300985817690213
pubmed: 28129098
Habenicht LM, Webb TL, Clauss LA, Dow SW, Quimby JM. Urinary cytokine levels in apparently healthy cats and cats with chronic kidney disease. J Feline Med Surg. 2013;15(2):99–104. https://doi.org/10.1177/1098612x12461007 .
doi: 10.1177/1098612x12461007
pubmed: 22989558
Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology. 2000;32(2):247–55. https://doi.org/10.1053/jhep.2000.9109 .
doi: 10.1053/jhep.2000.9109
pubmed: 10915731
Fukasawa H, Yamamoto T, Suzuki H, Togawa A, Ohashi N, Fujigaki Y, et al. Treatment with anti-TGF-β antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-β signaling. Kidney Int. 2004;65(1):63–74. https://doi.org/10.1111/j.1523-1755.2004.00393.x .
doi: 10.1111/j.1523-1755.2004.00393.x
pubmed: 14675037
Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang LB, Wakimoto H, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest. 2010;120(10):3520–9. https://doi.org/10.1172/Jci42028 .
doi: 10.1172/Jci42028
pubmed: 20811150
Leaf DE, Jacob KA, Srivastava A, Chen ME, Christov M, Juppner H, et al. Fibroblast growth factor 23 levels associate with AKI and Death in critical illness. J Am Soc Nephrol. 2017;28(6):1877–85. https://doi.org/10.1681/ASN.2016080836 .
doi: 10.1681/ASN.2016080836
pubmed: 28028134
Leaf DE, Siew ED, Eisenga MF, Singh K, Mc Causland FR, Srivastava A, et al. Fibroblast Growth Factor 23 Associates with death in critically ill patients. Clin J Am Soc Nephrol. 2018;13(4):531–41. https://doi.org/10.2215/CJN.10810917 .
doi: 10.2215/CJN.10810917
pubmed: 29519954
Finch NC, Geddes RF, Syme HM, Elliott J. Fibroblast growth factor 23 (FGF-23) concentrations in cats with early nonazotemic chronic kidney disease (CKD) and in healthy geriatric cats. J Vet Intern Med. 2013;27(2):227–33. https://doi.org/10.1111/jvim.12036 .
doi: 10.1111/jvim.12036
pubmed: 23363336
Galvao JFD, Nagode LA, Schenck PA, Chew DJ. Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease. J Vet Emerg Crit Car. 2013;23(2):134–62. https://doi.org/10.1111/vec.12036 .
doi: 10.1111/vec.12036
Geddes RF, Finch NC, Elliott J, Syme HM. Fibroblast growth factor 23 in Feline chronic kidney disease. J Vet Intern Med. 2013;27(2):234–41. https://doi.org/10.1111/jvim.12044 .
doi: 10.1111/jvim.12044
pubmed: 23398216
Geddes RF, Elliott J, Syme HM. Relationship between plasma fibroblast growth Factor-23 concentration and Survival Time in cats with chronic kidney disease. J Vet Intern Med. 2015;29(6):1494–501. https://doi.org/10.1111/jvim.13625 .
doi: 10.1111/jvim.13625
pubmed: 26403212
Liao YL, Chou CC, Lee YJ. The association of indoxyl sulfate with fibroblast growth factor-23 in cats with chronic kidney disease. J Vet Intern Med. 2019;33(2):686–93. https://doi.org/10.1111/jvim.15457 .
doi: 10.1111/jvim.15457
pubmed: 30779214
Deng LC, Alinejad T, Bellusci S, Zhang JS. Fibroblast growth factors in the management of Acute kidney Injury following ischemia-reperfusion. Front Pharmacol. 2020;11:426. https://doi.org/10.3389/fphar.2020.00426 .
doi: 10.3389/fphar.2020.00426
pubmed: 32322205
Wadey RM, Pinches MG, Jones HB, Riccardi D, Price SA. Tissue expression and correlation of a panel of urinary biomarkers following cisplatin-induced kidney injury. Toxicol Pathol. 2014;42(3):591–602. https://doi.org/10.1177/0192623313492044 .
doi: 10.1177/0192623313492044
pubmed: 23823703
Azzam R, Mokhtar ER. Serum cystatin c and urinary interleukin 18 as early indicators of acute kidney injury in icu patients. Al-azhar Assiut Med J. 2015;13(1).
Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z. Rodent models of AKI-CKD transition. Am J Physiol Ren Physiol. 2018;315(4):F1098–106. https://doi.org/10.1152/ajprenal.00199.2018 .
doi: 10.1152/ajprenal.00199.2018
Sequeira-Antunes B, Ferreira HA. Urinary biomarkers and point-of-care Urinalysis devices for early diagnosis and management of Disease: a review. Biomedicines. 2023;11(4). https://doi.org/10.3390/biomedicines11041051 .
Jung S, Kim J. Biomarker discovery and beyond for diagnosis of bladder diseases. Bladder (San Franc). 2020;7(1):e40. https://doi.org/10.14440/bladder.2020.813 .
doi: 10.14440/bladder.2020.813
pubmed: 32775482
Miller IJ, Peters SR, Overmyer KA, Paulson BR, Westphall MS, Coon JJ. Real-time health monitoring through urine metabolomics. Npj Digit Med. 2019;2. https://doi.org/10.1038/s41746-019-0185-y .
Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transpl. 2013;28(2):254–73. https://doi.org/10.1093/ndt/gfs380 .
doi: 10.1093/ndt/gfs380
Vanmassenhove J, Glorieux G, Lameire N, Hoste E, Dhondt A, Vanholder R, et al. Influence of severity of illness on neutrophil gelatinase-associated lipocalin performance as a marker of acute kidney injury: a prospective cohort study of patients with sepsis. Bmc Nephrol. 2015;16. https://doi.org/10.1186/s12882-015-0003-y .
Schley G, Koberle C, Manuilova E, Rutz S, Forster C, Weyand M, et al. Comparison of plasma and urine biomarker performance in Acute kidney Injury. PLoS ONE. 2015;10(12):e0145042. https://doi.org/10.1371/journal.pone.0145042 .
doi: 10.1371/journal.pone.0145042
pubmed: 26669323